These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
227 related items for PubMed ID: 15563517
1. Pharmacodynamic studies of amoxicillin against Streptococcus pneumoniae: comparison of a new pharmacokinetically enhanced formulation (2000 mg twice daily) with standard dosage regimens. Odenholt I, Cars O, Löwdin E. J Antimicrob Chemother; 2004 Dec; 54(6):1062-6. PubMed ID: 15563517 [Abstract] [Full Text] [Related]
2. Pulsatile delivery of amoxicillin against Streptococcus pneumoniae. Cha R, Rybak MJ. J Antimicrob Chemother; 2004 Dec; 54(6):1067-71. PubMed ID: 15486084 [Abstract] [Full Text] [Related]
3. Bactericidal activity of amoxicillin against non-susceptible Streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulation. Sevillano D, Calvo A, Giménez MJ, Alou L, Aguilar L, Valero E, Carcas A, Prieto J. J Antimicrob Chemother; 2004 Dec; 54(6):1148-51. PubMed ID: 15489246 [Abstract] [Full Text] [Related]
4. Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens including a pharmacokinetically enhanced formulation. Löwdin E, Cars O, Odenholt I. Clin Microbiol Infect; 2002 Oct; 8(10):646-53. PubMed ID: 12390283 [Abstract] [Full Text] [Related]
5. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000. Koeth LM, Jacobs MR, Good CE, Bajaksouzian S, Windau A, Jakielaszek C, Saunders KA. Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258 [Abstract] [Full Text] [Related]